There is a need for improved patient-physician communication, standardized monitoring of symptoms, and agreement on treatment goals in patients with myeloproliferative neoplasms (MPNs), according to results of an online survey involving >900 individuals. Participants included patients with MPNs (n=699) and physicians (n=219). Investigators measured MPN-related symptoms and the impact of MPNs on quality of life, the ability to work, and disease-management strategies. Among the results:

• The most frequent and severe symptom was fatigue.
• Most patients experienced reduced quality of life, even those with low symptom burden and low-risk scores.
• Many reported decreased ability to work and impaired overall activity.
• Physician feedback and blood counts were the most important indicators of treatment success.
• Patients often had different treatment goals than physicians.